AR101806A1 - DERIVATIVES OF 1-ACETYL-4-AMINO-1,2,3,4-TETRAHYDROQUINOLINE, PHARMACEUTICAL COMPOSITION THAT INCLUDES THEM AND THEIR USE IN THE TREATMENT OF AFFECTIONS MEDIATED BY A BROMODOMINUM INHIBITOR - Google Patents
DERIVATIVES OF 1-ACETYL-4-AMINO-1,2,3,4-TETRAHYDROQUINOLINE, PHARMACEUTICAL COMPOSITION THAT INCLUDES THEM AND THEIR USE IN THE TREATMENT OF AFFECTIONS MEDIATED BY A BROMODOMINUM INHIBITORInfo
- Publication number
- AR101806A1 AR101806A1 ARP150102888A ARP150102888A AR101806A1 AR 101806 A1 AR101806 A1 AR 101806A1 AR P150102888 A ARP150102888 A AR P150102888A AR P150102888 A ARP150102888 A AR P150102888A AR 101806 A1 AR101806 A1 AR 101806A1
- Authority
- AR
- Argentina
- Prior art keywords
- tetrahydroquinoline
- acetyl
- amino
- carboxamide
- dimethyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Abstract
Compuestos, a composiciones farmacéuticas que contienen tales compuestos y a su uso en terapia de afecciones para las cuales está indicado un inhibidor de bromodominio. Reivindicación 1: Un compuesto seleccionado del grupo que consiste en: 1-acetil-4-((5-cloropirimidin-2-il)amino)-2-metil-1,2,3,4-tetrahidroquinolina-6-carboxamida; 1-acetil-4-((5-cianopiridin-2-il)amino)-N-etil-2,3-dimetil-1,2,3,4-tetrahidroquinolina-6-carboxamida; 1-acetil-4-((5-cianopiridin-2-il)amino)-2,3-dimetil-1,2,3,4-tetrahidroquinolina-6-carboxamida; 1-acetil-4-((5-cianopiridin-2-il)amino)-2,3-dimetil-N-(tetrahidro-2H-piran-4-il)-1,2,3,4-tetrahidroquinolina-6-carboxamida; 1-acetil-4-((5-cianopiridin-2-il)amino)-N-((R)-2-hidroxipropil)-2,3-dimetil-1,2,3,4-tetrahidroquinolina-6-carboxamida; 1-acetil-4-((5-cianopiridin-2-il)amino)-N-((S)-2-hidroxipropil)-2,3-dimetil-1,2,3,4-tetrahidroquinolina-6-carboxamida; 1-acetil-4-((5-cloropirimidin-2-il)amino)-N-etil-2,3-dimetil-1,2,3,4-tetrahidroquinolina-6-carboxamida; 1-acetil-4-((5-cloropirimidin-2-il)amino)-2,3-dimetil-1,2,3,4-tetrahidroquinolina-6-carboxamida; 1-acetil-4-((5-cloropirimidin-2-il)amino)-2,3-dimetil-N-(tetrahidro-2H-piran-4-il)-1,2,3,4-tetrahidroquinolina-6-carboxamida; 1-acetil-4-((5-cloropirimidin-2-il)amino)-N-((S)-2-hidroxipropil)-2,3-dimetil-1,2,3,4-tetrahidroquinolina-6-carboxamida; 1-acetil-4-((5-cloropirimidin-2-il)amino)-N-((R)-2-hidroxipropil)-2,3-dimetil-1,2,3,4-tetrahidroquinolina-6-carboxamida; 1-acetil-4-((5-cianopirazin-2-il)amino)-2,3-dimetil-1,2,3,4-tetrahidroquinolina-6-carboxamida; 1-acetil-4-((5-cianopirazin-2-il)amino)-N-etil-2,3-dimetil-1,2,3,4-tetrahidroquinolina-6-carboxamida; 1-acetil-N-etil-4-((5-fluoropiridin-2-il)amino)-2,3-dimetil-1,2,3,4-tetrahidroquinolina-6-carboxamida; 1-acetil-4-((5-cloropirimidin-2-il)amino)-N-etil-2-metil-1,2,3,4-tetrahidroquinolina-6-carboxamida; y@@@1-acetil-4-((5-cianopiridin-2-il)amino)-N-etil-2-metil-1,2,3,4-tetrahidroquinolina-6-carboxamida; o una sal del mismo.Compounds, to pharmaceutical compositions containing such compounds and for use in therapy of conditions for which a bromodomain inhibitor is indicated. Claim 1: A compound selected from the group consisting of: 1-acetyl-4 - ((5-chloropyrimidin-2-yl) amino) -2-methyl-1,2,3,4-tetrahydroquinoline-6-carboxamide; 1-acetyl-4 - ((5-cyanopyridin-2-yl) amino) -N-ethyl-2,3-dimethyl-1,2,3,4-tetrahydroquinoline-6-carboxamide; 1-acetyl-4 - ((5-cyanopyridin-2-yl) amino) -2,3-dimethyl-1,2,3,4-tetrahydroquinoline-6-carboxamide; 1-acetyl-4 - ((5-cyanopyridin-2-yl) amino) -2,3-dimethyl-N- (tetrahydro-2H-pyran-4-yl) -1,2,3,4-tetrahydroquinoline-6 -carboxamide; 1-acetyl-4 - ((5-cyanopyridin-2-yl) amino) -N - ((R) -2-hydroxypropyl) -2,3-dimethyl-1,2,3,4-tetrahydroquinoline-6-carboxamide ; 1-acetyl-4 - ((5-cyanopyridin-2-yl) amino) -N - ((S) -2-hydroxypropyl) -2,3-dimethyl-1,2,3,4-tetrahydroquinoline-6-carboxamide ; 1-acetyl-4 - ((5-chloropyrimidin-2-yl) amino) -N-ethyl-2,3-dimethyl-1,2,3,4-tetrahydroquinoline-6-carboxamide; 1-acetyl-4 - ((5-chloropyrimidin-2-yl) amino) -2,3-dimethyl-1,2,3,4-tetrahydroquinoline-6-carboxamide; 1-acetyl-4 - ((5-chloropyrimidin-2-yl) amino) -2,3-dimethyl-N- (tetrahydro-2H-pyran-4-yl) -1,2,3,4-tetrahydroquinoline-6 -carboxamide; 1-acetyl-4 - ((5-chloropyrimidin-2-yl) amino) -N - ((S) -2-hydroxypropyl) -2,3-dimethyl-1,2,3,4-tetrahydroquinoline-6-carboxamide ; 1-acetyl-4 - ((5-chloropyrimidin-2-yl) amino) -N - ((R) -2-hydroxypropyl) -2,3-dimethyl-1,2,3,4-tetrahydroquinoline-6-carboxamide ; 1-acetyl-4 - ((5-cyanopyrazin-2-yl) amino) -2,3-dimethyl-1,2,3,4-tetrahydroquinoline-6-carboxamide; 1-acetyl-4 - ((5-cyanopyrazin-2-yl) amino) -N-ethyl-2,3-dimethyl-1,2,3,4-tetrahydroquinoline-6-carboxamide; 1-acetyl-N-ethyl-4 - ((5-fluoropyridin-2-yl) amino) -2,3-dimethyl-1,2,3,4-tetrahydroquinoline-6-carboxamide; 1-acetyl-4 - ((5-chloropyrimidin-2-yl) amino) -N-ethyl-2-methyl-1,2,3,4-tetrahydroquinoline-6-carboxamide; and @@@ 1-acetyl-4 - ((5-cyanopyridin-2-yl) amino) -N-ethyl-2-methyl-1,2,3,4-tetrahydroquinoline-6-carboxamide; or a salt thereof.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462049449P | 2014-09-12 | 2014-09-12 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR101806A1 true AR101806A1 (en) | 2017-01-11 |
Family
ID=54065889
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP150102888A AR101806A1 (en) | 2014-09-12 | 2015-09-10 | DERIVATIVES OF 1-ACETYL-4-AMINO-1,2,3,4-TETRAHYDROQUINOLINE, PHARMACEUTICAL COMPOSITION THAT INCLUDES THEM AND THEIR USE IN THE TREATMENT OF AFFECTIONS MEDIATED BY A BROMODOMINUM INHIBITOR |
Country Status (35)
Country | Link |
---|---|
US (1) | US10059699B2 (en) |
EP (1) | EP3191476B1 (en) |
JP (1) | JP6531167B2 (en) |
KR (1) | KR20170054421A (en) |
CN (1) | CN106687453B (en) |
AR (1) | AR101806A1 (en) |
AU (1) | AU2015314184B2 (en) |
BR (1) | BR112017004580A2 (en) |
CA (1) | CA2958159A1 (en) |
CL (1) | CL2017000587A1 (en) |
CO (1) | CO2017001601A2 (en) |
CR (1) | CR20170090A (en) |
CY (1) | CY1121369T1 (en) |
DK (1) | DK3191476T3 (en) |
DO (1) | DOP2017000058A (en) |
EA (1) | EA031679B9 (en) |
ES (1) | ES2705623T3 (en) |
HR (1) | HRP20182064T1 (en) |
HU (1) | HUE041694T2 (en) |
IL (1) | IL250397A0 (en) |
LT (1) | LT3191476T (en) |
MA (1) | MA40366A (en) |
MX (1) | MX2017003219A (en) |
PE (1) | PE20170675A1 (en) |
PH (1) | PH12017500348A1 (en) |
PL (1) | PL3191476T3 (en) |
PT (1) | PT3191476T (en) |
RS (1) | RS58135B1 (en) |
SG (1) | SG11201701043UA (en) |
SI (1) | SI3191476T1 (en) |
TR (1) | TR201820050T4 (en) |
TW (1) | TWI686389B (en) |
UY (1) | UY36292A (en) |
WO (1) | WO2016038120A1 (en) |
ZA (1) | ZA201700883B (en) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2970283B1 (en) | 2013-03-14 | 2020-11-11 | Boehringer Ingelheim International GmbH | Substituted 2-aza-bicyclo[2.2.1]heptane-3-carboxylic acid (benzyl-cyano-methyl)-amides inhibitors of cathepsin c |
AP2017009733A0 (en) | 2014-09-12 | 2017-02-28 | Boehringer Ingelheim Int | Spirocyclic inhibitors of cathepsin c |
US11028051B2 (en) * | 2016-12-13 | 2021-06-08 | St. Jude Children's Research Hospital | Tetrahydroquinoline-based bromodomain inhibitors |
JP2022509534A (en) | 2018-10-30 | 2022-01-20 | ニューベイション・バイオ・インコーポレイテッド | Heterocyclic compound as a BET inhibitor |
EP3997070A4 (en) | 2019-07-02 | 2023-07-26 | Nuvation Bio Inc. | Heterocyclic compounds as bet inhibitors |
EP4095128A1 (en) | 2021-05-25 | 2022-11-30 | Centre national de la recherche scientifique | Tetrahydroquinoline (thq) coumpounds |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010113498A1 (en) * | 2009-03-31 | 2010-10-07 | 興和株式会社 | Prophylactic and/or therapeutic agent for anemia comprising tetrahydroquinoline compound as active ingredient |
GB0919431D0 (en) | 2009-11-05 | 2009-12-23 | Glaxosmithkline Llc | Novel compounds |
GB0919432D0 (en) | 2009-11-05 | 2009-12-23 | Glaxosmithkline Llc | Use |
GB0919434D0 (en) * | 2009-11-05 | 2009-12-23 | Glaxosmithkline Llc | Novel compounds |
GB201106743D0 (en) | 2011-04-21 | 2011-06-01 | Glaxosmithkline Llc | Novel compounds |
GB201106750D0 (en) | 2011-04-21 | 2011-06-01 | Glaxosmithkline Llc | Novel compounds |
GB201107325D0 (en) | 2011-05-04 | 2011-06-15 | Glaxosmithkline Llc | Novel compounds |
SG11201506245QA (en) | 2013-03-14 | 2015-09-29 | Glaxosmithkline Ip No 2 Ltd | 2,3-disubstituted 1 -acyl-4-amino-1,2,3,4-tetrahydroquinoline derivatives and their use as bromodomain inhibitors |
-
2015
- 2015-09-09 PT PT15760461T patent/PT3191476T/en unknown
- 2015-09-09 ES ES15760461T patent/ES2705623T3/en active Active
- 2015-09-09 RS RS20190001A patent/RS58135B1/en unknown
- 2015-09-09 KR KR1020177008675A patent/KR20170054421A/en unknown
- 2015-09-09 HU HUE15760461A patent/HUE041694T2/en unknown
- 2015-09-09 SG SG11201701043UA patent/SG11201701043UA/en unknown
- 2015-09-09 CN CN201580048713.8A patent/CN106687453B/en not_active Expired - Fee Related
- 2015-09-09 SI SI201530529T patent/SI3191476T1/en unknown
- 2015-09-09 AU AU2015314184A patent/AU2015314184B2/en not_active Ceased
- 2015-09-09 MX MX2017003219A patent/MX2017003219A/en active IP Right Grant
- 2015-09-09 TR TR2018/20050T patent/TR201820050T4/en unknown
- 2015-09-09 LT LTEP15760461.2T patent/LT3191476T/en unknown
- 2015-09-09 WO PCT/EP2015/070665 patent/WO2016038120A1/en active Application Filing
- 2015-09-09 US US15/509,894 patent/US10059699B2/en active Active
- 2015-09-09 EA EA201790484A patent/EA031679B9/en not_active IP Right Cessation
- 2015-09-09 PE PE2017000388A patent/PE20170675A1/en unknown
- 2015-09-09 BR BR112017004580-0A patent/BR112017004580A2/en not_active Application Discontinuation
- 2015-09-09 PL PL15760461T patent/PL3191476T3/en unknown
- 2015-09-09 JP JP2017513723A patent/JP6531167B2/en not_active Expired - Fee Related
- 2015-09-09 CA CA2958159A patent/CA2958159A1/en not_active Abandoned
- 2015-09-09 EP EP15760461.2A patent/EP3191476B1/en active Active
- 2015-09-09 CR CR20170090A patent/CR20170090A/en unknown
- 2015-09-09 DK DK15760461.2T patent/DK3191476T3/en active
- 2015-09-09 MA MA040366A patent/MA40366A/en unknown
- 2015-09-10 AR ARP150102888A patent/AR101806A1/en unknown
- 2015-09-10 UY UY0001036292A patent/UY36292A/en not_active Application Discontinuation
- 2015-09-10 TW TW104129977A patent/TWI686389B/en not_active IP Right Cessation
-
2017
- 2017-02-01 IL IL250397A patent/IL250397A0/en unknown
- 2017-02-03 ZA ZA2017/00883A patent/ZA201700883B/en unknown
- 2017-02-17 CO CONC2017/0001601A patent/CO2017001601A2/en unknown
- 2017-02-27 PH PH12017500348A patent/PH12017500348A1/en unknown
- 2017-03-07 DO DO2017000058A patent/DOP2017000058A/en unknown
- 2017-03-09 CL CL2017000587A patent/CL2017000587A1/en unknown
-
2018
- 2018-12-06 HR HRP20182064TT patent/HRP20182064T1/en unknown
-
2019
- 2019-01-15 CY CY20191100049T patent/CY1121369T1/en unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2018000542A1 (en) | New phenoxymethyl derivatives. | |
BR112019006712A2 (en) | compound, pharmaceutical composition, composition for use in treating a disease, implantable element, and device. | |
AR101806A1 (en) | DERIVATIVES OF 1-ACETYL-4-AMINO-1,2,3,4-TETRAHYDROQUINOLINE, PHARMACEUTICAL COMPOSITION THAT INCLUDES THEM AND THEIR USE IN THE TREATMENT OF AFFECTIONS MEDIATED BY A BROMODOMINUM INHIBITOR | |
BR112018005497A2 (en) | heterocyclic compounds and their uses | |
CL2018000318A1 (en) | Compounds derived from pyridinone, bromodomain inhibitors; pharmaceutical composition comprising them; and its use in the treatment of cancer diseases. (divisional application 201600925) | |
NI201700020A (en) | AMINOPYRIMIDINYL COMPOUNDS AS JAK INHIBITORS | |
CR20190318A (en) | Benzooxazole derivatives as immunomodulators | |
SV2018005778A (en) | AROMATIC DERIVATIVES OF SULFONAMIDE | |
BR112016016844A2 (en) | HETEROCYCLIC COMPOUNDS | |
CR20170116A (en) | COMPOUNDS THAT INHIBIT THE PROTEIN MCL-1 | |
UY36342A (en) | NEW DERIVATIVES OF AMINOALQUILBENZOTIAZEPINAS AND USES OF THE SAME | |
BR112017007460A2 (en) | ror-gamma dihydropyrrolopyridine inhibitors | |
ECSP18073366A (en) | INDOLINE DERIVATIVES SUBSTITUTE AS INHIBITORS OF DENGUE VIRAL REPLICATION | |
CO2018004857A2 (en) | Dihydroimidazopirazinone derivatives used in cancer treatment | |
UY36112A (en) | IMIDAZO COMPOUNDS [4,5-C] QUINOLIN-2-ONA AND ITS USE TO TREAT CANCER | |
EA201692249A1 (en) | PHOSPHATIDYLINOSITOL-3-KINASE INHIBITORS | |
BR112016017996A2 (en) | 6-HETEROARYLOXY- OR 6-ARYLOXY-QUINOLINE-2-CARBOXAMIDES AND METHOD OF USE | |
UY36875A (en) | BROMODOMINIUM INHIBITING COMPOSITIONS FOR THE TREATMENT OF VARIOUS DISEASES | |
AR103680A1 (en) | BACE1 SELECTIVE INHIBITORS | |
BR112017003346B8 (en) | Pyrazolopyridine derivatives, their uses, and pharmaceutical composition | |
BR112015020139A2 (en) | therapeutic compounds and their uses | |
BR112017004589A2 (en) | compound, pharmaceutical composition, method for treating a patient, use of a compound, kit, and method for treating a smyd protein mediated disorder | |
AR100431A1 (en) | PIRIDINE PLADIENOLIDE COMPOUNDS AND METHODS OF USE | |
AR101414A1 (en) | PIRROLIDINONE DERIVATIVES AS METAP-2 INHIBITORS | |
DOP2016000308A (en) | COMPOUNDS OF 1, 3, 4-TIADIAZOL AND USE OF THE SAME FOR THE TREATMENT OF CANCER |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |